Are there clinically useful predictors and early warning signs for pending relapse?

Schizophrenia Research

Volumn 152, Issue 2-3, 2014, Pages 469-477

  Gaebel, Wolfgang ^a   Riesbeck, Mathias ^a  

^a Department of Orthopedic Surgery   (Germany)

Author keywords

Early warning signs; Predictors; Prodromal symptoms; Relapse; Schizophrenia

Indexed keywords

ARTICLE; HUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROGNOSIS; RELAPSE; SCHIZOPHRENIA; SYMPTOM ASSESSMENT; VULNERABLE POPULATION;

EARLY WARNING SIGNS; PREDICTORS; PRODROMAL SYMPTOMS; RELAPSE; SCHIZOPHRENIA;

DATABASES, BIBLIOGRAPHIC; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PRODROMAL SYMPTOMS; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84892873151     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.08.003     Document Type: Article

References (79)

1. Alvarez-Jimenez M., Gleeson J.F., Henry L.P., Harrigan S.M., Harris M.G., Amminger G.P., Killackey E., Yung A.R., Herrman H., Jackson H.J., McGorry P.D. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr. Res. 2011, 125:236-246.
2. Alvarez-Jimenez M., Priede A., Hetrick S.E., Bendall S., Killackey E., Parker A.G., McGorry P.D., Gleeson J.F. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr. Res. 2012, 139:116-128.
3. American Psychiatric Association (APA) Social and Occupational Functioning Assessment Scale (SOFAS). Diagnostic and Statistical Manual of Mental Disorders 2000, 817-818. American Psychiatric Association, Washington, DC, (text revision). fourth edition.
4. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 62:441-449.
5. Ascher-Svanum H., Zhu B., Faries D.E., Salkever D., Slade E.P., Peng X., Conley R.R. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10(2). (www.biomedcentral.com/1471-244X/10/2).
6. Birchwood M., Smith J., MacMillan F., Hogg B., Prasad R., Harvey C., Bering S. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol. Med. 1989, 19:649-656.
7. Birchwood M., Todd P., Jackson C. Early intervention in psychosis. The critical period hypothesis. Br. J. Psychiatry 1998, 172:53-59. (Suppl.).
8. Bustillo J., Buchanan R.W., Carpenter W.T. Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Schizophr. Bull. 1995, 21:553-559.
9. Caseiro O., Pérez-Iglesias R., Mata I., Martínez-Garcia O., Pelayo-Terán J.M., Tabares-Seisdedos R., Ortiz-García de la Foz V., Vázquez-Barquero J.L., Crespo-Facorro B. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J. Psychiatr. Res. 2012, 46(8):1099-1105.
10. Cechnicki A., Hanuszkiewicz I., Polczyk R., Bielańska A. Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia. Med. Sci. Monit. 2011, 17(5):CR277-CR283.
11. Chen E.Y., Hui C.L., Dunn E.L., Miao M.Y., Yeung W.S., Wong C.K., Chan W.F., Tang W.N. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr. Res. 2005, 77(1):99-104.
12. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002, 346(1):16-22.
13. Dawson M.E., Schell A.M., Rissling A., Ventura J., Subotnik K.L., Nuechterlein K.H. Psychophysiological prodromal signs of schizophrenic relapse: a pilot study. Schizophr. Res. 2010, 123(1):64-67.
14. DiMichele V., Bolino F., Mazza M., Roncone R., Casacchia M. Relapsing versus non relapsing course of schizophrenia: a cohort study in a community based mental health service. Epidemiol. Psichiatr. Soc. 2007, 16(1):50-58.
15. Docherty N.M., St-Hilaire A., Aakre J.M., Seghers J.P. Life events and high-trait reactivity together predict psychotic symptom increases in schizophrenia. Schizophr. Bull. 2009, 35(3):638-645.
16. Docherty N.M., St-Hilaire A., Aakre J.M., Seghers J.P., McCleery A., Divilbiss M. Anxiety interacts with expressed emotion criticism in the prediction of psychotic symptom exacerbation. Schizophr. Bull. 2011, 37(3):611-618.
17. Doering S., Müller E., Köpcke W., Pietzcker A., Gaebel W., Linden M., Müller P., Müller-Spahn F., Tegeler J., Schüssler G. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr. Bull. 1998, 24(1):87-98.
18. Drake R.J., Dunn G., Tarrier N., Bentall R.P., Haddock G., Lewis S.W. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J. Clin. Psychiatry 2007, 68(1):81-86.
19. Emsley R., Nuamah I., Hough D., Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr. Res. 2012, 138:29-34.
20. Falloon I.R.H. Relapse - a reappraisal of assessment of outcome in schizophrenia. Schizophr. Bull. 1984, 10(2):293-299.
21. Falloon I.R.H., Marshall G.N., Boyd J.L., Razani J., Woodsiverio C. Relapse in schizophrenia - a review of the concept and its definitions. Psychol. Med. 1983, 13(3):469-477.
22. Feldmann R., Buchkremer G., Minneker-Huegel E., Hornung P. Fragebogen zur Erfassung der emotionalen Familienatmosphäre (FEF). Diagnostica 1995, 41:334-348.
23. Fitzgerald P., de Castella A., Arya D., Simons W.R., Eggleston A., Meere S., Kulkarni J. The cost of relapse in schizophrenia and schizoaffective disorder. Australas. Psychiatry 2009, 17:265-272.
24. Fleischhacker W., Bergmann K., Perovich R. The Hillside Akathisia Scale (HAS): a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol. Bull. 1989, 25:222-226.
25. Frances A., Pincus H.A., First M.B. The Global Assessment of Functioning Scale (GAF). Diagnostic and Statistical Manual of Mental Disorders 1994, 32. American Psychiatric Association, Washington, DC. Fourth edition.
26. Gaebel W. Course typologies, treatment principles, and research concepts. Pharmacopsychiatry 2004, 37(Suppl. 2):S90-S97.
27. Gaebel W., Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr. Res. 2007, 95:19-29.
28. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Jockers-Scherübl M.C., Kühn K., Lemke M., Bechdolf A., Bender S., Degner D., Schlösser R., Schmidt L.G., Schmitt A., Jäger M., Buchkremer G., Falkai P., Klingberg S., Köpcke W., Maier W., Häfner H., Ohmann C., Salize H.J., Schneider F., Möller H.J. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2007, 68(11):1763-1774.
29. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Lemke M., Heuser I., Maier W., Huff W., Schmitt A., Sauer H., Riedel M., Klingberg S., Köpcke W., Ohmann C., Möller H.J. Relapse prevention in first-episode schizophrenia: maintenance vs. intermittent drug treatment with prodrome-based early intervention. Results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2011, 72:205-218. German Study Group on First-Episode Schizophrenia.
30. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Lemke M., Heuser I., Maier W., Klosterkötter J., Schmitt A., Sauer H., Riedel M., Klingberg S., Köpcke W., Ohmann C., Möller H.J. Rates and predictors of remission in first-episode schizophrenia within 1year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophr. Res 2013, German Study Group on First-Episode Schizophrenia, (May 1, pii: S0920-9964(13)00212-0, [Epub ahead of print]). 10.1016/j.schres.2013.04.012.
31. Gleeson J.F., Rawlings D., Jackson H.J., McGorry P.D. Early warning signs of relapse following a first episode of psychosis. Schizophr. Res. 2005, 80:107-111.
32. Gleeson J.F., Alvarez-Jimenez M., Cotton S.M., Parker A.G., Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr. Res. 2010, 119:79-88.
33. Goldman H.H., Skodol A.E., Lave T.R. Revising Axis V for DSM-IV. A review of measures of social functioning. Am. J. Psychiatry 1992, 149:1148-1156.
34. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 534-537. US Dept Health, Education and Welfare, Washington, DC. W. Guy (Ed.).
35. Clinical Global Impressions (CGI) Scale. ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 218-222. US Dept Health, Education, and Welfare, Washington, DC. W. Guy (Ed.).
36. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
37. Haro J.M., Novick D., Suarez D., Ochoa S., Roca M. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(5):1287-1292.
38. Hirsch S.R., Jolley A.G. The dysphoric syndrome in schizophrenia and its implications for relapse. Br. J. Psychiatry 1989, 155(Suppl. 5):46-50.
39. Hogan T.P., Awad A.G., Eastwood R.A. Self-report predictive of drug compliance in schizophrenia: reliability and discriminative ability. Psychol. Med. 1983, 13:177-183.
40. Holthausen E.A., Wiersma D., Cahn W., Kahn R.S., Dingemans P.M., Schene A.H., van den Bosch R.J. Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res. 2007, 149(1-3):71-80.
41. Hong J., Windmeijer F., Novick D., Haro J.M., Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:835-841.
42. Janke W., Erdmann G., Boucsein W. Stressverarbeitungsfragebogen (SVF) 1985, Hogrefe, Göttingen.
43. Jorgensen P. Early signs of psychotic relapse in schizophrenia. Br. J. Psychiatry 1998, 172:327-330.
44. Kane J.M. Treatment strategies to prevent relapse and encourage remission. J. Clin. Psychiatry 2007, 68(Suppl. 14):27-30.
45. Kay S.R., Opler L.A., Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) rating manual. Soc. Behav. Sci. Doc. 1986, 17:28-29.
46. Kemp R., David A. Psychological predictors of insight and compliance in psychotic patients. Br. J. Psychiatry 1996, 169:444-450.
47. Kishimoto T., Robenzadeh A., Leucht C., Leucht S., Watanabe K., Mimura M., Borenstein M., Kane J.M., Correll C.U. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull. 2014, 40:192-213.
48. Klingberg S., Schneider S., Conradt B., Schaub A., Wagner M., Wölwer W., Bechdolf A., Gaebel W., Buchkremer G. Individual Psychological Intervention for Relapse Prevention in Post Acute, First Episode Schizophrenia - 2-Year Follow-up of a Multicentric Randomized Clinical Trial 2013, (in preparation).
49. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
50. Leucht C., Heres S., Kane J.M., Kissling W., Davis J.M., Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011, 127:83-92.
51. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G., Davis J.M. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012, 379:2063-2071.
52. Levene J.E., Lancee W., Seeman M.V., Skinner H., Freeman S.J. Family and patient predictors of symptomatic status in schizophrenia. Can. J. Psychiatry 2009, 54(7):446-451.
53. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50:884-897.
54. Lipkovich I., Deberdt W., Csernansky J.G., Buckley P., Peuskens J., Kollack-Walker S., Zhang Y., Liu-Seifert H., Houston J.P. Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. J. Psychiatr. Res. 2007, 41(3-4):305-310.
55. Maier-Diewald W., Wittchen H.U., Hecht H., Werner-Eilert K. Die Münchner Ereignisliste (MEL) - Anwendungsmanual 1983, Max-Planck-Institut für Psychiatrie, München.
56. Malla A.K., Norman R.M.G. Prodromal symptoms in schizophrenia: a prospective investigation. Br. J. Psychiatry 1994, 164:487-493.
57. Marder S.R., Wirshing W.C., Van Putten T., Mintz J., McKenzie J., Johnston-Cronk K., Lebell M., Liberman R.P. Fluphenazine vs palcebo supplementation for prodromal signs of relapse in schizophrenia. Arch. Gen. Psychiatry 1994, 51:280-287.
58. Moher D., Schulz K.F., Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001, 285:1987-1991. CONSORT Group (Consolidated Standards of Reporting Trials).
59. Möller H.J., Riedel M., Jäger M., Wickelmaier F., Maier W., Kühn K.U., Buchkremer G., Heuser I., Klosterkötter J., Gastpar M., Braus D.F., Schlösser R., Schneider F., Ohmann C., Riesbeck M., Gaebel W. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int. J. Neuropsychopharmacol. 2008, 11:985-997.
60. Nuechterlein K.H., Dawson M.E. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr. Bull. 1984, 10:300-312.
61. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56:241-247.
62. Rund B.R., Melle I., Friis S., Johannessen J.O., Larsen T.K., Midbøe L.J., Opjordsmoen S., Simonsen E., Vaglum P., McGlashan T. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr. Res. 2007, 91(1-3):132-140.
63. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU) The UKU Side Effect Rating Scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatr. Scand. 1987, 76(Suppl. 334):81-94.
64. Schennach R., Obermeier M., Meyer S., Jäger M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkötter J., Heuser I., Maier W., Lemke M.R., Rüther E., Klingberg S., Gastpar M., Seemüller F., Möller H.J., Riedel M. Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr. Serv. 2012, 63(1):87-90.
65. Schooler N.R., Hogarty G.E., Weissman M.M. Social Adjustment Scale II (SAS II). Resource. Materials for Community Mental Health Evaluators Publication No (ADM) 290-330 1979, 79-328. Department of Health Education and Welfare, Washington, DC, US. W.A. Hargreaves, C.C. Attkisson, J.E. Sorenson (Eds.).
66. Schulz K.F., Altman D.G., Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann. Intern. Med. 2010, 152(11):726-732. CONSORT Group.
67. The Scottish First Episode Schizophrenia Study VIII: five-year follow-up: clinical and psychosocial findings. Br. J. Psychiatry 1992, 161:496-500. Scottish Schizophrenia Research Group.
68. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
69. Strauss J.S., Carpenter W. The prognosis of schizophrenia: rationale for a multidimensional concept. Schizophr. Bull. 1978, 4:56-67.
70. Subotnik K.L., Nuechterlein K.H. Prodromal signs and symptoms of schizophrenic relapse. J. Abnorm. Psychol. 1988, 97:405-412.
71. Subotnik K.L., Nuechterlein K.H., Ventura J., Gitlin M.J., Marder S., Mintz J., Hellemann G.S., Thornton L.A., Singh I.R. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am. J. Psychiatry 2011, 168(3):286-292.
72. Tarrier N., Barrowclough C., Bamrah J.S. Prodromal signs of relapse in schizophrenia. Soc. Psychol. Psychiatr. Epidemiol. 1991, 26:157-161.
73. Uçok A., Polat A., Cakir S., Genç A. One year outcome in first episode schizophrenia. Predictors of relapse. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256(1):37-43.
74. van Haren N.E., Cahn W., Hulshoff Pol H.E., Schnack H.G., Caspers E., Lemstra A., Sitskoorn M.M., Wiersma D., van den Bosch R.J., Dingemans P.M., Schene A.H., Kahn R.S. Brain volumes as predictor of outcome in recent-onset schizophrenia: a multi-center MRI study. Schizophr. Res. 2003, 64(1):41-52.
75. Watt D.C., Katz K., Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of standardized clinical and social assessment. Psychol. Med. 1983, 13:663-670.
76. Wiersma D., Nienhuis F.J., Sloof C., Giel R. Natural course of schizophrenic disorders: a 15year follow-up of a Dutch incidence cohort. Schizophr. Bull. 1998, 24:78-85.
77. Wölwer W., Buchkremer G., Häfner H., Klosterkötter J., Maier W., Möller H.J., Gaebel W. German research network on schizophrenia - bridging the gap between research and care. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:321-329.
78. Wölwer W., Brinkmeyer J., Riesbeck M., Freimüller L., Klimke A., Wagner M., Möller H.J., Klingberg S., Gaebel W. Neuropsychological impairments predict the clinical course in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 5):28-34. German Study Group on First Episode Schizophrenia.
79. Zubin J., Spring B. Vulnerability: a new view of schizophrenia. J. Abnorm. Psychol. 1977, 86:103-126.